Disseminated Intravascular Coagulation and Venous Thromboembolism Due to Acute Epstein-Barr Virus Infection

Bader, Mazen S.; Haroon, Babar; Trahey, Julia; Al-Musawi, Ali S.; Hawboldt, John

doi:10.1097/ipc.0b013e3181fc6e7c

Cited by 5 publications

(14 citation statements)

References 7 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, EBV-induced proinflammatory cytokines during inflammation play an important role in differential effects on the coagulation and fibrinolysis pathway. This may result in activation of the procoagulant pathway with subsequent thrombosis as reported previously (24) or an acquired hyperfibrinolytic state. This is the first report of a life-threatening, hemorrhagic diathesis in children with EBV-associated T-cell LPD, including their ICU course and outcome.…”

Section: Discussionmentioning

confidence: 85%

Severe Hemorrhagic Coagulopathy With Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder

Nawathe

Ravindranath

Satwani

et al. 2013

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

Severe Hemorrhagic Coagulopathy With Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder

Nawathe

Ravindranath

Satwani

et al. 2013

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…Interestingly, some of these patients were found to have elevated levels of aPL, a variable identified as favouring blood clot formation, as previously stated [95,96]. Although poorly understood, to the best of our knowledge, venous thrombosis in EBV patients might be related to oxidativeinducing endothelial cell injury and inflammation, with the consequent secretion of TF [69,87,95,96].…”

Section: Reviewmentioning

confidence: 86%

“…Data is still lacking regarding the impact of EBV infection on the development of thromboembolic events [ 69 ]. Despite being seldom reported mostly in immunocompromised patients, according to a few case-reports studies, this cardiovascular disease has also been identified in immunocompetent patients suffering from an acute EBV infection, which contributed to the worsening of their clinical outcome [ 69 , 87 , 95 – 98 ]. Interestingly, some of these patients were found to have elevated levels of aPL, a variable identified as favouring blood clot formation, as previously stated [ 95 , 96 ].…”

Section: Viral Carcinogenesis and Vte Incidencementioning

confidence: 99%

“…Despite being seldom reported mostly in immunocompromised patients, according to a few case-reports studies, this cardiovascular disease has also been identified in immunocompetent patients suffering from an acute EBV infection, which contributed to the worsening of their clinical outcome [ 69 , 87 , 95 – 98 ]. Interestingly, some of these patients were found to have elevated levels of aPL, a variable identified as favouring blood clot formation, as previously stated [ 95 , 96 ]. Although poorly understood, to the best of our knowledge, venous thrombosis in EBV patients might be related to oxidative-inducing endothelial cell injury and inflammation, with the consequent secretion of TF [ 69 , 87 , 95 , 96 ].…”

Section: Viral Carcinogenesis and Vte Incidencementioning

confidence: 99%

See 1 more Smart Citation

Map of thrombogenesis in viral infections and viral-driven tumours

et al. 2023

View full text Add to dashboard Cite

Viruses are pathogenic agents responsible for approximately 10% of all human cancers and significantly contribute to the global cancer burden. Until now, eight viruses have been associated with the development of a broad range of malignancies, including solid and haematological tumours. Besides triggering and promoting oncogenesis, viral infections often go hand-in-hand with haemostatic changes, representing a potential risk factor for venous thromboembolism (VTE). Conversely, VTE is a cardiovascular condition that is particularly common among oncological patients, with a detrimental impact on patient prognosis. Despite an association between viral infections and coagulopathies, it is unclear whether viral-driven tumours have a different incidence and prognosis pattern of thromboembolism compared to non-viral-induced tumours. Thus, this review aims to analyse the existing evidence concerning the association of viruses and viral tumours with the occurrence of VTE. Except for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection, which are associated with a high risk of VTE, little evidence exists concerning the thrombogenic potential associated with oncoviruses. As for tumours that can be induced by oncoviruses, four levels of VTE risk are observed, with hepatocellular carcinoma (HCC) and gastric carcinoma (GC) associated with the highest risk and nasopharyngeal carcinoma (NPC) associated with the lowest risk. Unfortunately, the incidence of cancer-related VTE according to tumour aetiology is unknown. Given the negative impact of VTE in oncological patients, research is required to better understand the mechanisms underlying blood hypercoagulability in viral-driven tumours to improve VTE management and prognosis assessment in patients diagnosed with these tumours.

show abstract

“… 11 , 12 VTE is also one of the hematological complications of infectious mononucleosis, although uncommon in immunocompetent patients. 13 In children with acute Varicella zoster virus (VZV) infection, PE and DVT have been frequently reported. 14 It can also cause stroke in children who suffer from chickenpox.…”

Section: Introductionmentioning

confidence: 99%

Venous thromboembolism in viral diseases: A comprehensive literature review

Zerangian

Erabi

Poudineh

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is known to be a common respiratory and/or cardiovascular complication in hospitalized patients with viral infections. Numerous studies have proven human immunodeficiency virus infection to be a prothrombotic condition. An elevated VTE risk has been observed in critically ill H1N1 influenza patients. VTE risk is remarkably higher in patients infected with the Hepatitis C virus in contrast to uninfected subjects. The elevation of D‐dimer levels supported the association between Chikungunya and the Zika virus and the rise of clinical VTE risk. Varicella‐zoster virus is a risk factor for both cellulitis and the consequent invasive bacterial disease which may take part in thrombotic initiation. Eventually, hospitalized patients infected with the coronavirus disease of 2019 (COVID‐19), the cause of the ongoing worldwide pandemic, could mainly suffer from an anomalous risk of coagulation activation with enhanced venous thrombosis events and poor quality clinical course. Although the risk of VTE in nonhospitalized COVID‐19 patients is not known yet, there are a large number of guidelines and studies on thromboprophylaxis administration for COVID‐19 cases. This study aims to take a detailed look at the effect of viral diseases on VTE, the epidemiology of VTE in viral diseases, and the diagnosis and treatment of VTE.

show abstract

Disseminated Intravascular Coagulation and Venous Thromboembolism Due to Acute Epstein-Barr Virus Infection

Cited by 5 publications

References 7 publications

Severe Hemorrhagic Coagulopathy With Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder

Severe Hemorrhagic Coagulopathy With Hemophagocytic Lymphohistiocytosis Secondary to Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder

Map of thrombogenesis in viral infections and viral-driven tumours

Venous thromboembolism in viral diseases: A comprehensive literature review

Contact Info

Product

Resources

About